FDA Inaction May Not Doom GSK Zofran MDL, 1st Circ. Hints
A First Circuit judge suggested Tuesday that a federal agency may not have blessed the label for GlaxoSmithKline's anti-nausea drug Zofran merely by declining to add a warning that it may...To view the full article, register now.
Already a subscriber? Click here to view full article